Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia

rifosine plus bortezomib, there were 2 PR's and 1 MR. Two additional MR's were observed on this combination after dexamethasone was added; both of these patients were previously refractory to the combination of bortezomib + dexamethasone without perifosine. Eleven patients remain on study and the phase II portion of the study is now open and enrolling.

A second poster presented by Dr. Richardson, entitled " Perifosine (KRX- 0401) + Low Dose Dexamethasone is Active in Patients with Relapsed and Refractory Multiple Myeloma (MM): Perifosine MM Investigator Group Phase II Multicenter Study Update" demonstrated that 78% of patients treated with perifosine plus low dose dexamethasone had at least stable disease (SD), including 26% that had a PR or MR. Patients continue on study now ranging from 6 months up through 1 year.

Dr. Andrzej Jakubowiak, Director of the myeloma program at the University of Michigan Cancer Center, presented a poster entitled "A Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results. Multiple Myeloma Research Consortium (MMRC) Trial", demonstrating early encouraging results, with 50% of patients achieving a partial response or better.

Commenting on the data, Dr. Richardson stated, "Perifosine's potential in combination with bortezomib, dexamethasone and other novel therapies to overcome drug-resistant multiple myeloma is promising. Our team of investigators, including top centers across the country and now incorporating the considerable resources of the MMRC for one of the trials, is committed to completing enrollment in our studies and evaluating future clinical strategies to improve patient outcome."

Perifosine in the treatment of Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia:

A poster entitled "A Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Wald
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
2. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/28/2014)... Colo. , Aug. 28, 2014   Venaxis, ... company focused on obtaining FDA clearance for and commercializing ... blood test for aiding in identifying children, adolescent, and ... at low risk for appendicitis, today announced it will ... Renshaw 16 th Annual Global Investment Conference being ...
(Date:8/28/2014)... Telik, Inc. (OTCQB: TELK), a clinical ... MabVax Therapeutics, Inc. on July 8, 2014, announced ... the development of its lead antibody program designated ... Company,s internally developed antibody discovery platform.  These preclinical ... based therapeutic and diagnostic products based on this ...
(Date:8/28/2014)... Ohio , Aug. 28, 2014  A ... competition in generics are adding pressure to pharmaceutical, ... resources. Company resources continue to shrink and approval ... This has led companies to look for additional ... commercialization and for keeping approved products on the ...
Breaking Medicine Technology:Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 44 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4
... PARSIPPANY, N.J., Sept. 13 PDI, Inc. (Nasdaq: PDII ... is scheduled to present at the UBS Global Life Sciences Conference ... Hyatt New York. The live webcast may be ... www.pdi-inc.com . The webcast will be archived for 90 days. ...
... SINGAPORE, Sept. 13 Novus Scientific Pte. Ltd today ... received Domain Specific Review Board (DSRB i.e. IRB equivalent) ... Closure After Lipectomy, TRAM /DIEP Flap ... Mesh. This is a randomized study, ...
Cached Medicine Technology:National University Hospital Singapore Receives DSRB Approval to Use TIGR® Matrix Surgical Mesh in a New Randomized Controlled TRAM Flap Study 2
(Date:8/28/2014)... York, New York (PRWEB) August 28, 2014 ... second federal bellwether trial of a transvaginal mesh ... by Ethicon, Inc., Bernstein Liebhard LLP reports. Court ... District of West Virginia indicate that the case ... had to undergo two revision surgeries, allegedly due ...
(Date:8/28/2014)... August 28, 2014 Allegheny ... today a regional partnership designed to advance sports ... for competitive young athletes, scholastic athletes and their ... Strong Body & Mind Initiative will offer a ... the physical and mental dynamics involved in pursuing ...
(Date:8/28/2014)... Sterling Heights, MI (PRWEB) August 28, 2014 ... stagnated in the last year, down by 0.13% in real ... G7, according to a new study by UHY, the international ... for the US’s small businesses in particular, the credit crunch ... in lending in last the last year have been wiped ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. 28, 2014 ... through the scalp to a specific network of brain structures ... In a small study of healthy young adults, researchers used ... in memory. That, in turn, boosted participants, performance on memory ... stimulation. During TMS, an electromagnetic coil is placed on ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 NJ ... Institute of North Jersey. , NJ Top Doc, ... is now a certified medical examiner for the ... certified by the department to perform all drug ... training in diagnosing and treating musculoskeletal disorders including ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Electrical Pulses to Scalp May Boost Memory: Study 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 3Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 3
... Queensland University researchers have ventured into a new approach ... The technique is targeted towards turning // the cancer ... patients. , ,Certain genes called tumor suppressor genes ... type of cancer. On the other hand, tumor-promoting genes ...
... research conducted at the Ohio State University shows that ... cancer deaths involves the loss of an essential muscle ... // dystrophy. , ,The study findings, which appear ... show that muscle cells lose significant amounts of the ...
... Hopkins scientists have developed a natural or rather biological ... with heart muscle cells. The newly developed pacemaker can ... of the heart in a more physiological way., ... give rise to the heart’s normal rhythm by stimulating ...
... deadly H5N1 virus, an article in the local newspaper Youth ... in the arm in the global fight against bird flu ... and the mechanism of transmission of the bird flu virus. ... Veterinary Centre have claimed the distinction of being the first ...
... conducted by Jefferson researchers has found that kidney disease ... disease than cholesterol. Studies conducted on mice have revealed ... hormone adiponectin may also have high levels of a ... , ,A negative correlation was found between urinary ...
... may reduce obesity and weight. Glucocorticodes are stress-reducing hormones, ... is under stress. This hormone reduces the stress // ... The researchers have found that by eating and drinking ... in weight and obesity. , ,Professor Ulrich-Lai and ...
Cached Medicine News:Health News:Cervical Cancer Can Now Be Better Handled With Gene Silencing Therapy 2Health News:Loss Of Dystrophin: Common Thread In Cancer And MS Muscle Wasting 2Health News:Novel Biological Pacemaker Under Construction for Weak Hearts 2Health News:Vietnamese Scientists Unravel Genetic Code Of Bird Flu Virus 2
... Introducing the new PRONEB® ULTRA compressor. ... treatment time while delivering more medication to ... PARI LC PLUS® or PARI LC STAR® ... are optimized for inhalation and retention into ...
... Compressed Air., ,Allied Healthcares Timeter® PCS 414 ... other air compressors that you may wonder if ... PCS 414 features a durable, mar-resistant steel case ... unit weighs only 26.5 pounds. The PCS 414 ...
... DC powered compressor nebulizer system available. ... to take nebulizer treatments away from ... the included AC power adapter or ... The integral reusable jet nebulizer kit ...
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
Medicine Products: